Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Multiplicom's CF and FMF Dx; Enzymatics' Archer FusionPlex Heme; CHLA's RB1 Test


Multiplicom has launched a next-generation sequencing-based test for cystic fibrosis and plans to launch a test for familial Mediterranean fever in July. The kits will have the CE-IVD marking. Multiplicom has also achieved ISO 13485 accreditation, which certifies the company to design, develop, manufacture, and distribute in vitro molecular diagnostic kits that identify genomic and somatic variants.

Enzymatics has launched its Archer FusionPlex Heme panel, a targeted next-generation sequencing-based assay that detects fusions involving 19 genes associated with hematological malignancies. The assay is based on the company's proprietary anchored multiplex PCR-based enrichment technology.

The Children's Hospital Los Angeles has launched a next-generation sequencing-based retinoblastoma test, RB1 NextGen. The test evaluates germline mutations in the entire RB1 gene.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.